Skip to main content
TECON BIOLOGY Co.LTD logo

TECON BIOLOGY Co.LTD — Investor Relations & Filings

Ticker · 002100 ISIN · CNE000001PZ9 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,493 across all filing types
Latest filing 2021-04-22 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 002100

About TECON BIOLOGY Co.LTD

https://www.tcsw.com.cn

TECON BIOLOGY Co.LTD operates an integrated industrial chain focused on animal health and nutrition. The company specializes in the research, development, and manufacturing of veterinary biological products, including a comprehensive range of vaccines and diagnostic reagents for livestock. Its operations encompass the production of high-quality animal feed and the management of large-scale breeding programs, with a primary focus on pig farming and meat processing. By leveraging advanced biotechnology and standardized production systems, the company provides comprehensive solutions for livestock management and food safety. Key activities include the formulation of specialized animal nutrition products and the implementation of rigorous biosecurity protocols across its facilities to ensure the quality and reliability of its agricultural outputs.

Recent filings

Filing Released Lang Actions
2020年度非公开发行股票募集资金使用可行性分析报告（修订稿）
Capital/Financing Update Classification · 95% confidence The document is titled as a "2020年度非公开发行股票募集资金使用可行性分析报告 (修订稿)" which translates to "2020 Annual Non-public Issuance of Shares Fundraising Feasibility Analysis Report (Revised)". It details the use of funds raised from a non-public stock issuance, including investment projects, financial evaluations, and the impact on the company's operations and financial status. The content focuses on the feasibility and planned use of the raised capital rather than reporting financial results or earnings. This aligns with a Capital/Financing Update, as it provides an update on fundraising activities and capital usage plans. The document length is substantial (over 11,000 characters), indicating it is a full report rather than a brief announcement. There is no indication that this is an Annual Report, Earnings Release, or other categories. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2021-04-22 Chinese
独立董事对担保等事项的独立意见
Governance Information Classification · 95% confidence The document is titled as an "Independent Directors' Special Opinion" for the company Tian Kang Biological Co., Ltd. It references regulatory guidelines from the China Securities Regulatory Commission and Shenzhen Stock Exchange, and covers topics such as related party transactions, external guarantees, executive compensation, internal control self-assessment, audit firm reappointment, profit distribution proposals, related party transactions, and adjustments to non-public stock issuance. The document is a detailed independent directors' report providing opinions on various governance and financial matters for the fiscal year ending December 31, 2020. It is not a full annual report, audit report, or earnings release, but rather a governance-related opinion document by independent directors. This fits best under the category of Governance Information (CGR), which includes reports detailing the company's internal rules, board structure, and governance practices. The document length (3185 characters) and content confirm it is not a brief announcement or a certification letter, but a substantive governance opinion report.
2021-04-22 Chinese
关于调整公司非公开发行股票方案、预案、募集资金使用可行性分析报告修订情况说明的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding adjustments to a company's non-public stock issuance plan, including changes to the issuance scale, fundraising use, and feasibility analysis report. It details specific changes in the number of shares to be issued and the allocation of raised funds. The document is a formal public announcement about financing activities, specifically about a non-public stock issuance plan adjustment. It does not contain full financial statements or comprehensive financial performance data, so it is not an Annual Report (10-K) or Interim Report (IR). It is not a report publication announcement since it contains substantive content rather than just a notice of report availability. The content fits best under Capital/Financing Update (CAP) as it relates to fundraising and capital structure changes.
2021-04-22 Chinese
关于2020年度利润分配预案的公告
Notice of Dividend Amount Classification · 95% confidence The document is an announcement from Tian Kang Biological Co., Ltd. regarding the 2020 annual profit distribution plan. It includes details about the profit allocation, dividend per share, legal compliance, and independent directors' opinions. The document is relatively short (1402 characters) and focuses on the dividend distribution proposal rather than presenting full financial statements or comprehensive annual results. It is not a full Annual Report (10-K) or Interim Report (IR), nor is it a simple notice of dividend amount without detailed context. The document is best classified as a Notice of Dividend Amount (DIV) because it announces the dividend payment plan, amounts, and related shareholder information for the fiscal year 2020.
2021-04-22 Chinese
中信建投证券股份有限公司关于天康生物股份有限公司2020年度内部控制规则落实自查表的核查意见
Audit Report / Information Classification · 95% confidence The document is a verification opinion from a sponsoring institution (中信建投证券股份有限公司) regarding the internal control self-assessment form of 天康生物股份有限公司 for the year 2020. It references internal control rules, governance structure, and compliance with regulatory requirements. The document is short (856 characters) and does not contain actual financial statements or detailed financial data. It is essentially an audit or verification opinion on internal control compliance rather than a full audit report or annual report. Given the focus on internal control verification and the nature of the document, it fits best under Audit Report / Information (AR). FY 2020
2021-04-22 Chinese
2020年年度审计报告
Audit Report / Information Classification · 95% confidence The document is titled '审计报告' which translates to 'Audit Report'. It contains detailed audit opinions, basis for audit opinions, key audit matters, and responsibilities of management and auditors. It includes comprehensive financial statements such as consolidated and parent company balance sheets, income statements, cash flow statements, and notes to the financial statements. The document is lengthy (15,000 characters) and contains actual financial data and detailed audit information. This matches the definition of an Audit Report / Information (AR) rather than a full Annual Report (10-K) or a simple announcement. Therefore, the document is classified as an Audit Report / Information (AR). FY 2020
2021-04-22 Chinese

Browse filings by year

21 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.